Irvine Barclay Theater Operating Company, Inc. – Trademark Portfolio
Entity Type: 54
Irvine Barclay Theater Operating Company, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include THE BARCLAY, TRIO BARCLAY, and THE BARCLAY JAZZ & BEYOND ORCHESTRA. The owner is based in Irvine, CA.
4199 Campus Drive
Suite 275
Irvine, CA 92612
Showing of trademarks Trademarks
Trademark Classifications
Irvine Barclay Theater Operating Company, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does Irvine Barclay Theater Operating Company, Inc. have?
Irvine Barclay Theater Operating Company, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does Irvine Barclay Theater Operating Company, Inc. file in?
Irvine Barclay Theater Operating Company, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 41 (Education & Entertainment). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.
What are Irvine Barclay Theater Operating Company, Inc.'s most well-known trademarks?
Irvine Barclay Theater Operating Company, Inc.'s registered trademark portfolio includes well-known marks such as THE BARCLAY, TRIO BARCLAY, and THE BARCLAY JAZZ & BEYOND ORCHESTRA. These are among 4 currently registered trademarks in the portfolio.
What is Irvine Barclay Theater Operating Company, Inc.'s trademark registration success rate?
Irvine Barclay Theater Operating Company, Inc. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.